Toggle light / dark theme

Glass, rubber and plastics all belong to a class of matter called amorphous solids. And in spite of how common they are in our everyday lives, amorphous solids have long posed a challenge to scientists.

Since the 1910s, scientists have been able to map in 3D the atomic structures of crystals, the other major class of solids, which has led to myriad advances in physics, chemistry, biology, , geology, nanoscience, drug discovery and more. But because aren’t assembled in rigid, repetitive atomic structures like crystals are, they have defied researchers’ ability to determine their with the same level of precision.

Until now, that is.

The team found that feeding mice a high fat diet disrupted the circuit, which led not only to weight gain but also to signs of anxiety and depression on standard behavioral tests.

When the researchers used genetic techniques to restore the normal functioning of nerve receptors in the circuit, this resulted in weight loss and eliminated the animals’ signs of anxiety and depression.


A recent study in mice has found that eating a high fat diet may disrupt a newly discovered neural circuit that affects both mood and appetite.

A team of researchers from the Harbin Institute of Technology along with partners at the First Affiliated Hospital of Harbin Medical University, both in China, has developed a tiny robot that can ferry cancer drugs through the blood-brain barrier (BBB) without setting off an immune reaction. In their paper published in the journal Science Robotics, the group describes their robot and tests with mice. Junsun Hwang and Hongsoo Choi, with the Daegu Gyeongbuk Institute of Science and Technology in Korea, have published a Focus piece in the same journal issue on the work done by the team in China.

For many years, medical scientists have sought ways to deliver drugs to the brain to treat health conditions such as brain cancers. Because the brain is protected by the skull, it is extremely difficult to inject them directly. Researchers have also been stymied in their efforts by the BBB—a filtering mechanism in the capillaries that supply blood to the brain and that blocks foreign substances from entering. Thus, simply injecting drugs into the bloodstream is not an option. In this new effort, the researchers used a defense cell type that naturally passes through the BBB to carry drugs to the brain.

To build their tiny robots, the researchers exposed groups of white blood cells called neutrophils to tiny bits of magnetic nanogel particles coated with fragments of E. coli material. Upon exposure, the neutrophils naturally encased the tiny robots, believing them to be nothing but E. coli bacteria. The microrobots were then injected into the bloodstream of a test mouse with a cancerous tumor. The team then applied a to the robots to direct them through the BBB, where they were not attacked, as the identified them as normal neutrophils, and into the brain and the tumor. Once there, the robots released their cancer-fighting drugs.

An Israeli company said Wednesday that it received European approval for its rapid coronavirus test and it was poised to help kickstart international travel.

The handheld SpectraLIT machine eliminates the need for complex lab equipment by shining light through samples and giving immediate results using the spectral signature.

This means that staff in airport booths who are currently tasked with collecting test samples and dispatching them to labs will simply have a machine at hand and be able to give passengers results after just 20 seconds of analysis.

A $2 million federal grant will enable Houston-based PolyVascular to launch human trials of what it hails as the first polymer-based heart valve for children.

In conjunction with the grant, Dr. Will Clifton has joined the medical device company as chief operating officer. He will oversee the grant as principal investigator, and will manage the company’s operations and R&D. Clifton is president and co-founder of Houston-based Enventure, a medical innovation incubator and education hub. He previously was senior director of medical affairs at Houston-based Procyrion, a clinical-stage medical device company.

PolyVascular’s Phase II grant came from the Small Business Innovation Research (SBIR) program, which promotes technological projects.

Dr Joan Mannick, Head of Research and Development at Life Biosciences, discusses the #geroscience approach in disease treatment and the exciting work being done at Life Biosciences.


#Ageing is the greatest risk factor for almost every chronic disease. Multiple studies have shown that ageing is a modifiable risk factor that can be targeted therapeutically.

In this week’s #HealthyLongevity #webinar session, Dr Joan Mannick, Head of Research and Development at Life Biosciences, discusses the #geroscience approach in disease treatment and the exciting work being done at Life Biosciences.

Buck Institute researchers have discovered and are developing a novel, non-invasive biomarker test that can be used to measure and track performance of senolytics: a class of drugs that selectively eliminate senescent cells. The discovery is expected to play a major role in efforts to develop treatments that would battle a myriad of chronic age-related conditions that range from arthritis to lung disease to Alzheimer’s disease and glaucoma. This biomarker is a unique signaling lipid metabolite, normally exclusively intracellular, but is released when senescent cells are forced to die. This metabolite is detectible in blood and urine, making non-invasive testing possible. With a growing list of senolytic drugs in development, detecting this metabolite via a companion test could verify performance of senolytic candidates.

“The list of age-related diseases definitively linked to cellular keeps growing, as does the number of biotech companies racing to develop drugs to eliminate senescent ,” said Buck professor Judith Campisi, Ph.D., senior scientist on the study. “While the field has never been more promising, the lack of a simple biomarker to measure and track efficacy of these treatments has been a hindrance to progress. We are excited to bring this new biomarker to the field and look forward to it being used in the clinic.”

People into aging/longevity research probably know all of what’s here already.


Aubrey de Grey has been the leading voice for antiaging, aging reversal and aging damage repair for over twenty years. He founded the SENS non-profit (Strategies for Engineered Negligible Senescence (SENS). There have been six antiaging companies that have been directly spun out of SENS is researching the hardest problems related to fixing aging damage.

Repairing damage in five of the areas of aging are now highly active areas of biotech research.

SENS has helped fund lab work to show that mitochondrial mutations and loss of elasticity in the extracellular matrix can be repaired. SENS is now helping to pioneer combination antiaging therapies.

“Last year’s stimulus was about keeping the economy going, but these companies didn’t use these resources to retain their workers. These are companies that are polluting the environment, increasing the deadliness of the pandemic and letting go of their workers.”


Figures show 77 companies received $8.2bn under tax changes related to Covid relief and yet almost every one let workers go.

The results of this study confirm a direct link, on a molecular level, between the gut microbiome and brain function.


Summary: Consuming high levels of sugar-sweetened beverages early in life may lead to memory problems during adulthood. Researchers found, compared to rats who consumed only water, those who drank sugar-sweetened beverages had difficulties in memory recall associated with the hippocampus. The study also found a link between specific changes in gut bacteria in rats who drank sugary drinks and impaired brain function.

Source: USC

New research shows how drinking sugary beverages early in life may lead to impaired memory in adulthood.